Therapeutic antibodies in ophthalmology: Old is new again

mAbs

Volumn 2, Issue 2, 2010, Pages 176-180

  Magdelaine Beuzelin, Charlotte ^a,b,c   Pinault, Coralie ^c   Paintaud, Gilles ^a,b,c   Watier, Hervé ^a,b,c  

^a UNIVERSITÉ DE TOURS   (France)

^b CNRS   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Anti VEGF monoclonal antibodies; Bevacizumab; FcRn; Pharmacology; Ranibizumab; Serotherapy

Indexed keywords

ANTIBODY; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; RANIBIZUMAB; RECOMBINANT ANTIBODY;

CONJUNCTIVITIS; DRUG RESEARCH; EYE DISEASE; HUMAN; MEDICAL RESEARCH; NOTE; RETINA MACULA AGE RELATED DEGENERATION;

ANTIBODIES, MONOCLONAL; BLOOD-RETINAL BARRIER; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; MACULAR DEGENERATION; OPHTHALMOLOGY; RECEPTORS, FC; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953654063     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.2.11205     Document Type: Note

References (35)

1. Roux E, Martin L, Chaillou A. Trois cents cas de diphtérie traités par le sérum antidiphtérique. Ann de l'Inst Pasteur 1894; 8:640-61.
2. Coppez H. Un cas de diphtérie oculaire guéri par la sérothérapie. Journal med et chir 1894; 42:665-70.
3. Coppez H. Un second cas de diphtérie oculaire traité par la sérothérapie. Journal med et chir 1894; 47:745-54.
4. Pes O. Sulla etiologia e sulla cura de alcune congiuntiviti pseudo-membranose. Gior. d. r. Accad di med di Torino 1895; 1:393-418.
5. Jessop W. Two cases of membranous conjunctivitis in which Loeffler's bacillus was found; treatment by anti-toxin. Trans Oph Soc UK 1895; 55-64.
6. Hoppe J. Mittheilungen aus der Praxis über die Heilserumbehandlung der Diphtherie; ein Fall von Augen- und Rachendiphtherie, behandelt mit Behring'schem Heilserum Deutsche Med Wochenschr 1895; 12:199-200.
7. Ewetzky T. Ueber die Bindehautdiphterie und ihre Behandlung mit Heilserum. Berliner klin Wochenschr 1896; 33:685-9.
8. Desseaux J. Une petite épidémie de diphtérie à St-Vaast-du-Val. Normandie méd 1895; 11:1-8.
9. Gayet A. Un essai d'application de la sérothérapie à la diphtérie conjonctivale. Arch d'opht 1895; 137-43.
10. Morax V. La conjonctivite diphtérique: son traitement par le sérum antitoxique. Ann d'ocul 1895; 113:238-55.
11. Aubineau E. Essai sur l'application de la sérothérapie dans le traitement de la diphtérie conjonctivale. Paris: H Jouve 1895; 1-59.
12. Funck M. Manuel de sérothérapie antidiphtérique. Paris:Carré 1895; 1-161.
13. Coppez H. Des conjonctivites pseudo-membraneuses; histoire, formes cliniques, traitement (Thèse de Doctorat spécial). Bruxelles: H. Lamertin 1897; 1-239.
14. von Pirquet C, Schick B. Die Serumkrankheiten. Leipzig & Wien: F. Deuticke 1905; 1-144.
15. Coppez H, Danis M. Rétinite exsudative maculaire sénile. Arch D'opht 1923; 129-46.
16. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium III. Senile disciform degeneration. Am J Ophthalmol 1967; 63:617-44.
17. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-9.
18. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991; 53:217-39.
19. Magdelaine-Beuzelin C, Kaas Q, Wehbi V, Ohresser M, Jefferis R, Lefranc M-P, et al. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment. Crit Rev Oncol Hematol 2007; 64:210-25.
20. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57:4593-9.
21. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, et al. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 1998; 6:1153-67.
22. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293:865-81.
23. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006; 142:660-8.
24. 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999; 27:536-44.
25. Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J. Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci 2003; 44:2141-6.
26. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46:726-33.
27. Lefranc M-P, Pommié C, Ruiz M, Giudicelli V, Foulquier E, Truong L, et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol 2003; 27:55-77.
28. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascularization age-related macular degeneration. Ophthalmic Surg Laser Imaging 2005; 36:331-5.
29. Steinbrook R. The price of sight-ranibizumab, bevacizumab and the treatment of macular degeneration. N Engl J Med 2006; 355:1409-12.
30. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114:855-9.
31. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114:2179-82.
32. Bolz M, Michels S, Geitzenauer W, Prager F, Schmidt-Erfurth U. Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment. Br J Ophthalmol 2007; 91:785-9.
33. Saishin Y, Saishin Y, Takahashi K, Lima e Silva R, Hylton D, Rudge JS, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003; 195:241-8.
34. Kim H, Fariss RN, Zhang C, Robinson SB, Thill M, Csaky KG. Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci 2008; 49:2025-9.
35. Loisel S, Ohresser M, Pallardy M, Daydé D, Berthou C, Cartron G, et al. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 2007; 62:34-42.